Literature DB >> 16467164

Loss of human leucocyte antigen class I and gain of class II expression are early events in carcinogenesis: clues from a study of Barrett's oesophagus.

S Rajendra1, R Ackroyd, N Karim, C Mohan, J J Ho, M K Kutty.   

Abstract

BACKGROUND: Human leucocyte antigen (HLA) expression is altered in oesophageal carcinomas compared with normal tissue. It is unclear, however, whether this phenotype precedes malignant transformation or results as a consequence of it. AIM: To investigate HLA class I and II expression in Barrett's oesophagus and normal squamous oesophageal tissue.
METHODS: Asian patients with Barrett's oesophagus (n = 64) and a control group (n = 60) with a normal oesophagus but without reflux symptoms were recruited using endoscopic and histopathological criteria. Tissue samples were stained with monoclonal antibodies specific for HLA-ABC, HLA-DR alpha chain or HLA-DP/DQ/DR, and scored semiquantitatively. The results of immunohistochemical staining were correlated with clinical and histopathological characteristics of patients.
RESULTS: Marked expression of HLA-ABC was observed in 50% of Barrett's oesophagus sections as compared with 68.3% of controls (p = 0.038). HLA-DR staining was seen in 51.6% of Barrett's oesophagus samples versus 11.7% of controls (p<0.001). Expression of HLA-DP/DQ/DR was evident in 73.4% of oesophageal intestinal metaplasia tissue as opposed to 18.3% of controls (p<0.001). Importantly, a total loss of HLA-ABC and a concomitant gain of HLA-DP/DQ/DR expression were seen in 37.5% of patients with Barrett's oesophagus but in none of the controls (p<0.001). Interestingly, this phenotype was associated positively with dysplasia (adjusted p, p* = 0.031) but negatively with non-steroidal anti-inflammatory drug use (p* = 0.004).
CONCLUSIONS: HLA class I expression is down regulated and class II expression is up regulated in Barrett's oesophagus. As these changes predate malignant transformation, altered major histocompatibility complex expression may be a key event in disease progression, possibly in facilitating evasion from immune surveillance.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16467164      PMCID: PMC1860487          DOI: 10.1136/jcp.2005.031575

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  33 in total

1.  Barrett's esophagus: age, prevalence, and extent of columnar epithelium.

Authors:  A J Cameron; C T Lomboy
Journal:  Gastroenterology       Date:  1992-10       Impact factor: 22.682

2.  Gene expression in Barrett's mucosa: acute and chronic adaptive responses in the oesophagus.

Authors:  J Jankowski
Journal:  Gut       Date:  1993-12       Impact factor: 23.059

3.  HLA-DR expression is associated with excellent prognosis in squamous cell carcinoma of the larynx.

Authors:  F Esteban; F Ruiz-Cabello; A Concha; M Pérez-Ayala; J A Sánchez-Rozas; F Garrido
Journal:  Clin Exp Metastasis       Date:  1990 Jul-Aug       Impact factor: 5.150

Review 4.  Natural history of HLA expression during tumour development.

Authors:  F Garrido; T Cabrera; A Concha; S Glew; F Ruiz-Cabello; P L Stern
Journal:  Immunol Today       Date:  1993-10

5.  Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression.

Authors:  C M D'Urso; Z G Wang; Y Cao; R Tatake; R A Zeff; S Ferrone
Journal:  J Clin Invest       Date:  1991-01       Impact factor: 14.808

Review 6.  MHC expression on human tumors--its relevance for local tumor growth and metastasis.

Authors:  F Garrido; F Ruiz-Cabello
Journal:  Semin Cancer Biol       Date:  1991-02       Impact factor: 15.707

7.  Heat shock protein 70 and HLA-DR molecules tissue expression. Prognostic implications in colorectal cancer.

Authors:  A C Lazaris; G E Theodoropoulos; P S Davaris; D Panoussopoulos; L Nakopoulou; C Kittas; B C Golematis
Journal:  Dis Colon Rectum       Date:  1995-07       Impact factor: 4.585

8.  Altered HLA expression by metastatic cervical carcinoma cells as a factor in impaired immune surveillance.

Authors:  C G Hilders; I M Munoz; Y Nooyen; G J Fleuren
Journal:  Gynecol Oncol       Date:  1995-06       Impact factor: 5.482

9.  Analysis of MHC class I and II expression in relation to presence of HPV genotypes in premalignant and malignant cervical lesions.

Authors:  F V Cromme; C J Meijer; P J Snijders; A Uyterlinde; P Kenemans; T Helmerhorst; P L Stern; A J van den Brule; J M Walboomers
Journal:  Br J Cancer       Date:  1993-06       Impact factor: 7.640

10.  Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas.

Authors:  F V Cromme; J Airey; M T Heemels; H L Ploegh; P J Keating; P L Stern; C J Meijer; J M Walboomers
Journal:  J Exp Med       Date:  1994-01-01       Impact factor: 14.307

View more
  5 in total

Review 1.  Future approaches for inner ear protection and repair.

Authors:  Seiji B Shibata; Yehoash Raphael
Journal:  J Commun Disord       Date:  2010-04-08       Impact factor: 2.288

Review 2.  Microbiome, innate immunity, and esophageal adenocarcinoma.

Authors:  Jonathan Baghdadi; Noami Chaudhary; Zhiheng Pei; Liying Yang
Journal:  Clin Lab Med       Date:  2014-09-26       Impact factor: 1.935

3.  Management of Barrett's oesophagus and intramucosal oesophageal cancer: a review of recent development.

Authors:  Shanmugarajah Rajendra; Prateek Sharma
Journal:  Therap Adv Gastroenterol       Date:  2012-09       Impact factor: 4.409

4.  Barrett's Esophagus.

Authors:  Shanmugarajah Rajendra; Prateek Sharma
Journal:  Curr Treat Options Gastroenterol       Date:  2014-06

5.  Variations in the MHC region confer risk to esophageal squamous cell carcinoma on the subjects from high-incidence area in northern China.

Authors:  Fang-Fang Shen; Wen-Bin Yue; Fu-You Zhou; Ying Pan; Xue-Ke Zhao; Yan Jin; Xin Song; Bei Li; Xue-Na Han; Sa Tang; Yan Li; Guo Yuan; Li-Sha Chen; Ya-Li Liu; Yan-Long Hu; Xiu-Min Li; Jing-Li Ren; Li-Dong Wang
Journal:  PLoS One       Date:  2014-03-04       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.